ALLOGENE THERAPEUTICS INC. - COMMON STOCK

Allogene Therapeutics Reports Second Quarter 2023 Financial Results and Business Update

02 авг 2023 16:02:00 Источник Nasdaq GlobeNewswire

Allogene Therapeutics to Report Second Quarter 2023 Financial Results on August 2, 2023

26 июл 2023 08:30:00 Источник Nasdaq GlobeNewswire

Allogene Therapeutics Provides Additional ALLO-501/501A Phase 1 Data in an Oral Presentation at the International Conference on Malignant Lymphoma (ICML) Lugano

15 июн 2023 09:30:00 Источник Nasdaq GlobeNewswire

Allogene Therapeutics Announces Departure of Chief Financial Officer

14 июн 2023 08:00:01 Источник Nasdaq GlobeNewswire

Allogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-501/501A in Large B Cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) Lugano

09 июн 2023 18:25:18 Источник Nasdaq GlobeNewswire

Allogene Therapeutics Presents Updated ALLO-501/501A Phase 1 Data in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting

03 июн 2023 09:00:00 Источник Nasdaq GlobeNewswire

Allogene Therapeutics Announces Participation in Three Upcoming Investor Conferences

24 май 2023 08:30:00 Источник Nasdaq GlobeNewswire

Allogene Therapeutics Announces Encore Presentation of Phase 1 Data from the ALLO-501/501A Trials in Large B Cell Lymphoma at the European Hematology Association (EHA) Hybrid Congress

11 май 2023 11:50:32 Источник Nasdaq GlobeNewswire

Allogene Therapeutics Reports First Quarter 2023 Financial Results and Business Update

03 май 2023 16:02:00 Источник Nasdaq GlobeNewswire

Allogene Therapeutics Announces Presentation of Phase 1 Data from the ALLO-501/501A Trials in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting

26 апр 2023 10:06:38 Источник Nasdaq GlobeNewswire

Allogene Therapeutics to Report First Quarter 2023 Financial Results on May 3, 2023

25 апр 2023 08:30:00 Источник Nasdaq GlobeNewswire

Allogene Therapeutics Appoints Timothy Moore as Chief Technical Officer

20 апр 2023 16:05:00 Источник Nasdaq GlobeNewswire

Allogene Therapeutics Presents Interim Phase 1 Data on ALLO-316 in Renal Cell Carcinoma at the American Association of Cancer Research (AACR) Annual Meeting

17 апр 2023 10:15:00 Источник Nasdaq GlobeNewswire

Allogene Therapeutics Announces Participation in Four Upcoming Investor Conferences

13 апр 2023 08:30:00 Источник Nasdaq GlobeNewswire

Allogene Therapeutics Publishes 2022 Annual Environmental, Social and Governance (ESG) Report

30 мар 2023 08:30:00 Источник Nasdaq GlobeNewswire

Allogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-316 at the American Association of Cancer Research (AACR) Annual Meeting

14 мар 2023 17:30:48 Источник Nasdaq GlobeNewswire

Allogene Therapeutics Announces Participation in Two Upcoming Investor Conferences

02 мар 2023 08:30:00 Источник Nasdaq GlobeNewswire

Allogene Therapeutics Announces Publication of Industry-Advancing Case Study on Chromosomal Rearrangement in Molecular Therapy 

01 мар 2023 08:30:00 Источник Nasdaq GlobeNewswire

Allogene Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

28 фев 2023 16:02:00 Источник Nasdaq GlobeNewswire

Allogene Therapeutics to Report Fourth Quarter and Year-End 2022 Financial Results on February 28, 2023

21 фев 2023 08:30:00 Источник Nasdaq GlobeNewswire